General

Pronunciation:
ok-ri-plas-min


Trade Name(s)

  • Jetrea

Ther. Class.
ocular agents

Pharm. Class.
enzymes

Indications

Symptomatic treatment of vitreomacular adhesion (VMA).

Action

A proteolytic enzyme that dissolves the protein matrix present in vitreomacular adhesions.

Therapeutic Effect(s):

Dissolution of vitreomacular adhesion with improved vision.

Pharmacokinetics

Absorption: Minimal absorption

Distribution: Action is primarily local

Metabolism and Excretion: Rapidly degraded following administration

Half-life: Unknown.

TIME/ACTION PROFILE (VMA resolution)

ROUTEONSETPEAKDURATION
Intravitrealwithin 1 wk3 wk6 mos or more

Contraindication/Precautions

Contraindicated in:

  • None noted.

Use Cautiously in:

  • Lactation:Effects are not know, use caution;
  • OB: Use during pregnancy only if clearly needed;
  • Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

May be due to procedure

EENT: blurred vision, conjunctival hemorrhage, ↓ visual acuity, eye pain, macular hole, vitreous floaters, retinal edema, anterior chamber cell, cataract, conjunctival hyperemia, dry eye, dyschromatopsia (yellow vision), ↑ intraocular pressure, intraocular inflammation/infection, intraocular hemorrhage, iritis, lens subluxation, macular edema, metamorphopsia (distorted vision), photophobia, photopsia (perceived light flashes), retinal degeneration, retinal detachment, vitreous detachment

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

None noted.

Route/Dosage

Intravitreal: (Adults) 0.125 mg injected as a single dose.

Availability

Solution for intravitreal injection: 0.375 mg/0.3 mL

Assessment

  • Monitor for elevation in intraocular pressure following injection.
  • Monitor visual acuity periodically following injection; may lead to decrease in vision.

Potential Diagnoses

Implementation

  • Ocriplasmin must be administered by a qualified physician.
  • Intravitreal: Remove vial from freezer and allow to thaw for few min at room temperature. Solution is clear and colorless without particles; do not administer solutions that are discolored or contain particulate matter. Withdraw all solution from vial with a 19 gauge needle. Replace needle with 30 gauge needle and expel excess air and solution to 0.1 mL. Discard unused solution. Administer adequate anesthesia and a broad spectrum antibiotic as per protocol. Intravitreal injection is done via aseptic technique. Repeat administration in same eye is not recommended.
    • Wait 7 days before treating other eye if necessary.

Patient/Family Teaching

  • Explain procedure for intravitreal injection to patient.
  • Advise patient to notify health care professional immediately if signs and symptoms of intraocular inflammation/infection (eye redness, sensitivity to light, eye pain, change in vision) occurs.
  • May cause visual changes. Advise patient to avoid driving and other activities requiring good vision until response to medication is known.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Improved vision in patients with vitreomacular adhesions.

ocriplasmin is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Learn more.

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - ocriplasmin ID - 110137 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110137/all/ocriplasmin PB - F.A. Davis Company ET - 16 DB - Pediatrics Central DP - Unbound Medicine ER -